View:
Download DOC
Download PDF
Download XLS
tm2321018-1_s1a - none - 2.7343888s
​
As filed with the Securities and Exchange Commission on July 12, 2023
Registration Statement No. 333-273070​
​
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
Amendment No. 1
to
FORM S-1
REGISTRATION STATEMENT
under the
SECURITIES ACT OF 1933
YIELD10 BIOSCIENCE, INC.
(Exact Name of Registrant as Specified in Its Charter)
​
Delaware
(State or other jurisdiction of
incorporation or organization)​
​ ​
2870
(Primary Standard Industrial
Classification Code Number)​
​ ​
04-3158289
(IRS Employer
Identification No.)
​
19 Presidential Way
Woburn, Massachusetts 01801
(617) 583-1700
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)​
​
Dr. Oliver P. Peoples
President & Chief Executive Officer
Yield10 Bioscience, Inc.
19 Presidential Way
Woburn, Massachusetts 01801
(617) 583-1700
(Name, address, including zip code, and telephone number, including area code, of agent for service)​
​
Copies to:
Joel I. Papernik, Esq.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
919 Third Avenue
New York, NY 10022
(212) 935-3000
Approximate date of commencement of proposed sale to the public: From time to time after this registration statement becomes effective.
If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☒
If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
​
Large accelerated filer
☐
​
 ​ ​
Accelerated filer
☐
​
 ​
​
Non-accelerated filer
☒
​
 ​ ​
Smaller reporting company
☒
​
 ​
​ ​ ​ ​
Emerging growth company
☐
​
 ​
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐.
The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
​
​
​
 
EXPLANATORY NOTE
Yield10 Bioscience, Inc. is filing this Amendment No. 1 to its registration statement on Form S-1 (File No. 333-273070) as an exhibits-only filing. Accordingly, this amendment consists only of the facing page, this explanatory note, Item 16 of Part II of the Registration Statement, the signature page to the Registration Statement and the filed exhibit. The remainder of the Registration Statement is unchanged and has therefore been omitted.
 
2
​
 
PART II INFORMATION NOT REQUIRED IN PROSPECTUS
Item 16.   Exhibits and Financial Statement Schedules.
(a)   The exhibits listed below are filed as part of or incorporated by reference into this Registration Statement on Form S-1. Where certain exhibits are incorporated by reference from a previous filing, the exhibit numbers and previous filings are identified in parentheses.
​
Exhibit
Number
​ ​
Exhibit Description
​ ​
Filed
Herewith
​ ​
Previously
Filed
​ ​
Incorporated
by Reference
herein from
Form or
Schedule
​ ​
Filing
Date
​ ​
SEC File/​
Reg.
Number
​
​
3.1.1
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 10-Q (Exhibit 3.1)
​ ​
8/9/2018
​ ​
001-33133
​
​
3.1.2
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 8-K (Exhibit 3.1)
​ ​
1/15/2020
​ ​
001-33133
​
​
3.1.3
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 8-K (Exhibit 3.1)
​ ​
11/20/2019
​ ​
001-33133
​
​
3.1.4
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 8-K (Exhibit 3.2)
​ ​
11/20/2019
​ ​
001-33133
​
​
3.2
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 10-Q (Exhibit 3.1)
​ ​
11/10/2021
​ ​
001-33133
​
​
4.1
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 10-Q (Exhibit 4.1)
​ ​
11/12/2020
​ ​
001-33133
​
​
4.2
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 8-K (Exhibit 4.1)
​ ​
7/5/2017
​ ​
001-33133
​
​
4.3
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form S-1/A (Exhibit 4.3)
​ ​
12/15/2017
​ ​
333-221283
​
​
4.4
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 8-K (Exhibit 4.1)
​ ​
11/20/2019
​ ​
001-33133
​
​
4.5
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 8-K (Exhibit 4.1)
​ ​
5/4/2023
​ ​
001-33133
​
​
4.6
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 8-K (Exhibit 4.2)
​ ​
5/4/2023
​ ​
001-33133
​
​
5.1
​ ​ ​ ​ ​ ​ ​
X
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
10.1†
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form S-1/A (Exhibit 10.3)
​ ​
10/20/2006
​ ​
333-135760
​
 
3
​
 
​
Exhibit
Number
​ ​
Exhibit Description
​ ​
Filed
Herewith
​ ​
Previously
Filed
​ ​
Incorporated
by Reference
herein from
Form or
Schedule
​ ​
Filing
Date
​ ​
SEC File/​
Reg.
Number
​
​
10.1.1†
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form S-1/A (Exhibit 10.3.1)
​ ​
10/20/2006
​ ​
333-135760
​
​
10.1.2†
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form S-1/A (Exhibit 10.3.2)
​ ​
10/20/2006
​ ​
333-135760
​
​
10.1.3†
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form S-1/A (Exhibit 10.3.3)
​ ​
10/20/2006
​ ​
333-135760
​
​
10.2†
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 10-Q (Exhibit 10.1)
​ ​
8/13/2015
​ ​
001-33133
​
​
10.2.1†
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 10-K (Exhibit 10.3.1)
​ ​
3/25/2015
​ ​
001-33133
​
​
10.2.2†
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 10-K (Exhibit 10.3.2)
​ ​
3/25/2015
​ ​
001-33133
​
​
10.2.3†
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 10-K (Exhibit 10.3.3)
​ ​
3/25/2015
​ ​
001-33133
​
​
10.3†
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 8-K (Exhibit 10.1)
​ ​
5/30/2023
​ ​
001-33133
​
​
10.3.1†
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 10-K (Exhibit 10.2.5)
​ ​
3/28/2019
​ ​
001-33133
​
​
10.3.2†
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 10-K (Exhibit 10.2.6)
​ ​
3/25/2020
​ ​
001-33133
​
​
10.4†
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 10-K (Exhibit 10.3)
​ ​
3/30/2017
​ ​
001-33133
​
​
10.5†
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 10-K (Exhibit 10.4)
​ ​
3/30/2017
​ ​
001-33133
​
 
4
​
 
​
Exhibit
Number
​ ​
Exhibit Description
​ ​
Filed
Herewith
​ ​
Previously
Filed
​ ​
Incorporated
by Reference
herein from
Form or
Schedule
​ ​
Filing
Date
​ ​
SEC File/​
Reg.
Number
​
​
10.6†
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 10-K (Exhibit 10.6)
​ ​
3/30/2017
​ ​
001-33133
​
​
10.7†
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 10-K (Exhibit 10.8)
​ ​
3/30/2017
​ ​
001-33133
​
​
10.8†
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 10-K (Exhibit 10.9)
​ ​
3/30/2017
​ ​
001-33133
​
​
10.9†
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form S/1/A (Exhibit 10.14)
​ ​
10/20/2006
​ ​
333-135760
​
​
10.10
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 8-K (Exhibit 10.1)
​ ​
6/17/2015
​ ​
001-33133
​
​
10.11
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 8-K (Exhibit 10.1)
​ ​
1/26/2016
​ ​
001-33133
​
​
10.12
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 10-K (Exhibit 10.20)
​ ​
3/30/2017
​ ​
001-33133
​
​
10.13
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 8-K (Exhibit 10.1)
​ ​
7/5/2017
​ ​
001-33133
​
​
10.14@
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 10-Q (Exhibit 10.2)
​ ​
8/9/2018
​ ​
001-33133
​
​
10.15
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 8-K (Exhibit 10.1)
​ ​
3/15/2019
​ ​
001-33133
​
 
5
​
 
​
Exhibit
Number
​ ​
Exhibit Description
​ ​
Filed
Herewith
​ ​
Previously
Filed
​ ​
Incorporated
by Reference
herein from
Form or
Schedule
​ ​
Filing
Date
​ ​
SEC File/​
Reg.
Number
​
​
10.16
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 8-K (Exhibit 10.1)
​ ​
11/20/2019
​ ​
001-33133
​
​
10.17
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 8-K (Exhibit 10.1)
​ ​
8/25/2020
​ ​
001-33133
​
​
10.18
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 10-K (Exhibit 10.18)
​ ​
3/14/2023
​ ​
001-33133
​
​
10.19
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 8-K (Exhibit 1.1)
​ ​
1/24/2023
​ ​
001-33133
​
​
10.20
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 8-K (Exhibit 10.1)
​ ​
5/4/2023
​ ​
001-33133
​
​
21.1
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Form 10-K (Exhibit 21.1)
​ ​
3/16/2021
​ ​
001-33133
​
​
23.1
​ ​ ​ ​ ​ ​ ​
X
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
23.2
​ ​ ​ ​ ​ ​ ​
X
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
24.1
​ ​ ​ ​ ​ ​ ​
X
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
101.INS
​ ​ XBRL Instance Document. ​ ​ ​ ​ ​
X
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
101.SCH
​ ​ XBRL Taxonomy Extension Schema. ​ ​ ​ ​ ​
X
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
101.CAL
​ ​ XBRL Taxonomy Extension Calculation Linkbase. ​ ​ ​ ​ ​
X
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
101.DEF
​ ​ XBRL Taxonomy Extension Definition Linkbase. ​ ​ ​ ​ ​
X
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
 
6
​
 
​
Exhibit
Number
​ ​
Exhibit Description
​ ​
Filed
Herewith
​ ​
Previously
Filed
​ ​
Incorporated
by Reference
herein from
Form or
Schedule
​ ​
Filing
Date
​ ​
SEC File/​
Reg.
Number
​
​
101.LAB
​ ​ XBRL Taxonomy Extension Label Linkbase. ​ ​ ​ ​ ​
X
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
101.PRE
​ ​ XBRL Taxonomy Extension Presentation Linkbase. ​ ​ ​ ​ ​
X
​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
107
​ ​ ​ ​
X
​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
​
†
Management contract or compensatory plan or arrangement.
​
@
Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (“[***]”) because the identified confidential portions (i) are not material and (ii) is the type of information that the Company treats as private or confidential.
​
 
7
​
 
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Amendment No. 1 to the Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Woburn, Massachusetts, on July 12, 2023.
YIELD10 BIOSCIENCE, INC.
By:
/s/ Oliver P. Peoples
​
​
Oliver P. Peoples President and Chief
Executive Officer
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-1 has been signed below by the following persons in the capacities and on the dates indicated.
​
/s/ OLIVER P. PEOPLES
​
Oliver P. Peoples, Ph.D.
​ ​ President and Chief Executive Officer and Director (Principal Executive Officer) ​ ​
July 12, 2023
​
​
/s/ CHARLES B. HAASER
​
Charles B. Haaser
​ ​ Vice President, Finance, and Chief Accounting Officer (Principal Financial and Accounting Officer) ​ ​
July 12, 2023
​
​
*
​
Sherri M. Brown
​ ​ Director ​ ​
July 12, 2023
​
​
*
​
Richard W. Hamilton, Ph.D.
​ ​ Director ​ ​
July 12, 2023
​
​
*
​
WILLIE LOH, Ph.D.
​ ​ Director ​ ​
July 12, 2023
​
​
*
​
Anthony J. Sinskey, Sc.D.
​ ​ Director ​ ​
July 12, 2023
​
​
*
​
Robert L. Van Nostrand
​ ​ Chairman ​ ​
July 12, 2023
​
​
*By:
/s/ Oliver P. Peoples, Ph.D.
​
​
Oliver P. Peoples, Ph.D., Attorney-In-Fact
 
8

 

Exhibit 107

 

Calculation of Filing Fee Table

 

Form S-1

(Form Type)

 

Yield10 Bioscience, Inc.

(Exact name of Registrant as Specified in its Charter)

 

Table 1 — Newly Registered Securities

 

Security Type Security Class
Title		 Fee Calculation
Rule (3)		 Amount
Registered (1)		 Proposed
Maximum
Offering Price
Per Unit (2)		 Maximum
Aggregate
Offering Price		 Fee Rate Amount of
Registration
Fee
Equity Common stock, par value $0.01 per share 457(c) 1,006,710 $1.965 $1,978,185.15 $0.00011020 $218.00
Total Offering Amount       $1,978,185.15   $218.00
Total Fees Previously Paid           —
Total Fee Offsets           —
Net Fee Due             $218.00

 

(1)Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended, this Registration Statement shall also cover any additional shares of common stock of Yield10 Bioscience, Inc. (the “Registrant”) that become issuable with respect of the securities identified in the above table by reason of any stock dividend, stock split, recapitalization or other transaction effected without the Registrant’s receipt of consideration that results in an increase in the number of outstanding shares of Registrant’s common stock.

 

(2)Estimated in accordance with Rules 457(c) solely for purposes of calculating the registration fee on the basis of $1.965, the weighted average of the high and low prices of the Registrant’s common stock as reported on the Nasdaq Capital Market on June 28, 2023.

 

(3)Consists of 1,006,710 shares of common stock registered for resale by the selling security holders named in this Registration Statement, issuable upon the exercise of outstanding warrants.